Cidara Therapeutics : Corporate Presentation - January 2021

CORPORATE PRESENTATION

1	L E A D I N G T H E S C I E N C E O F P R O T E C T I O N	J A N U A R Y 2 0 2 1

F O R WA R D - LO O K I N G S TAT E M E N T S

T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .

The words "believe," "may," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward- looking statements. Such statements include, but are not limited to, statements regarding Cidara's research and development efforts; preclinical and clinical development activities; plans, projections and expectations for and the potential effectiveness, safety and benefits of, its product candidates, including rezafungin, the Cloudbreak platform and CD377; Cidara's ability to successfully commercialize its product candidates; and potential ability to achieve milestones under its collaboration with Mundipharma, and receipt of the related milestone payments; and advancement of its strategic plans.

This presentation also contains estimates and other statistical data made by independent parties and by Cidara relating to market size and growth and other data about Cidara's industry. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Projections, assumptions and estimates of the future performance of the markets in which Cidara operates are necessarily subject to a high degree of uncertainty and risk, including, Cidara's ability to obtain additional financing; the success and timing of Cidara's preclinical studies, clinical trials and other research and development activities; receipt of necessary regulatory approvals for development and commercialization, as well as changes to applicable regulatory laws in the United States Securities and Exchange Commission, under the heading "Risk Factors."

Additional risks and uncertainties may emerge from time to time, and it is not possible for Cidara's management to predict all risk factors and uncertainties. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

These slides are not intended to and do not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

2

C I DA R A I N V ES T M E N T T H ES I S

L e a d i n g s c i e n c e o n l o n g - a c t i n g a n t i f u n g a l a n d a n t i v i r a l p r e v e n t i o n a n d t r e a t m e n t

REZAFUNGIN	1st antifungal under development in 14 years for treatment and prophylaxis
Treatment - Phase 3	ReSTORE: treatment of candidemia and invasive candidiasis
Prophylaxis - Phase 3	ReSPECT: prevention in high risk hematology (BMT) setting
Validation	Significant ex-US/ex-Japan partnership with Mundipharma

CLOUDBREAK AVCs	Modular antiviral platform for prevention & treatment
Influenza A+B	Target: 1st effective 'universal flu' product
RSV, HIV, CoV	Progressing multiple pre-clinical programs

3

L EA D I N G T H E S C I E N C E O N A N T I F U N G A L & A N T I V I R A L P R E V E N T I O N & T R EAT M E N T

ANTIFUNGAL PROGRAMS

Product	Indications	IND-Enabling	Phase 1	Phase 2	Phase 3
Rezafungin Treatment	Candidemia and Invasive Candidiasis
Rezafungin Prevention	IFD in Blood & Marrow Transplant Patients
ANTIVIRAL PROGRAMS
Product	Indications	Discovery	Preclinical	IND-Enabling	Phase 1
CD377	Single Dose	̴4 months
Prevention & Treatment	Influenza - 3 months
CD388	Influenza - Single Dose	6̴ months
Prevention & Treatment
RSV AVC	RSV
Prevention & Treatment
HIV AVC	HIV
Prevention & Treatment
SARS-CoV-2 AVC	SARS-CoV-2
Prevention & Treatment

4

C I DA R A' S P I P E L I N E TA RG E T S M U LT I P L E U N M E T M E D I C A L N E E D S

REZAFUNGINCLOUDBREAK

ANTIFUNGALANTIVIRAL

5

A N T I F U N G A L S A R E H I S T O R I C A L L Y B I G D R U G S G L O B A L L Y

P e a k A n n u a l G l o b a l S a l e s ( $ M )

Diflucan 1,000

Vfend 800

Noxafil 720

Cancidas 680

Ambisome 510

Mycamine 370

6 Source: IQVIA for all products in their respective peak sales year, other than Noxafil (2018 Merck Annual Report) and Diflucan (www.pharmaceuticalonline.com Feb 7, 2000)

A N T I F U N G A L D R U G D E V E LO P M E N T H A S DW I N D L E D

	Number of New Antifungals
5	5	1

1980

POLYENES

1990

2000

2010

2020

• amphotericin lipid forms (3)

AZOLES

•	itraconazole	•	posaconazole
•	fluconazole	•	voriconazole

ECHINOCANDINS

•	micafungin
•	caspofungin	rezafungin
•	anidulafungin

7 Includes antifungals approved for systemic fungal infections.

R E Z A F U N G I N I S D E S I G N E D T O T A R G E T A L A R G E M A R K E T S E G M E N T

CANDIDEMIA			73%	Percentage of
		Invasive Fungal
AND CANDIDIASIS				Infections

Rezafungin

OTHER

12%

			ASPERGILLOSIS
15%			AND MUCORMYCOSIS

• Non-inferiorityto generic voriconazole
• Failed Phase 3 Candida trial
• No prophylaxis label

8 Source: Diagnostic Microbiology and Infectious Disease. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012

A N T I F U N G A L L AU N C H O U T PA C ES A N T I BA C T E R I A L S

Cresemba's launch in the US has been a success, despite its limitations

U . S . S A L E S P O S T L A U N C H : C R E S E M B A V S . A N T I B A C T E R I A L S

Annualized Sales ($M)

120													ANTIFUNGAL
80												AVYCAZ
												DALVANCE	ANTIBACTERIALS
40												ZERBAXA
												ORBACTIV
0
1	2	3	4	5	6	7	8	9	10	11	12	13

Launch Quarter

9 Cresemba (isavuconazole) is a triazole launched in Q2 2015 by Astellas in the US. In 2017, Pfizer acquired rights to izavuconazole from Basilea for EU, China, 16 Asia Pac countries. Source for sales data: IQVIA

A N T I F U N G A L S C A N H AV E G R EAT E R VA LU E T H A N A N T I BA C T E R I A L S

ANTIFUNGALS

RIGHTS

DEAL ($ MILLION)

DATA AVAILABLE AT SIGNING

	0	200	400	600				P3	NDA	Marketed
			P2
Cidara / Mundipharma: Rezafungin	Ex-US;ex-Japan
				568
Basilea / Pfizer:	Ex-US;ex-Japan
						725

ANTIBACTERIALS

0

200 400 600

P3

NDA

Marketed

P2

Melinta / Menarini: Delafloxacin

Ex-US;ex-Japan

120

Paratek / Zai Labs: Omadacycline

China

Melinta / Menarini:

Ex-US;ex-Japan

265

Vabomere, Orbactiv & Minocin

10

R E Z A F U N G I N : A N OV E L LO N G - A C T I N G EC H I N O C A N D I N I N P H A S E 3

N+

O

N+	O	OH	O	-
	O
	O	H O
HO
	N	N
H3C	H
	O
N
H3C	O HN	OH
HO	NH O	N	CH3		O
O	H
N
HO
		OH
	O
	OH
HO

STRUCTURAL MODIFICATION IS DESIGNED TO YIELD IMPROVED CHEMICAL & BIOLOGICAL PROPERTIES

Design Features	Potential Benefit
Designed for prolonged PK1	once weekly dosing in clinical studies1
Designed for high exposures2,3	potential for improved efficacy
Observed absence of toxic degradation products4	potential for improved safety
No DDIs5 and favorable hepatic & renal safety1,4	compatible with other medications

11	1.	STRIVE Ph2 Trial. Thompson et al. CID Sept 2020	4.	Ong et al. AAC November 2016
2.	Lakota et al. AAC November 2017	5.	Ong et al. BBMT March 2019

3. Zhao et al. AAC October 2017

L A RG E M A R K E T, B U T EC H I N O C A N D I N S A R E CO N S T R A I N E D TO DAY

$4.2 Billion

$0.5 Polyenes

$1.1 Echinocandins

$2.6 Azoles

OUTPATIENT

INPATIENT

TREATMENTPROPHYLAXIS

AzolesAzoles/Bactrim

MarketedAzoles/Bactrim Echinocandins

12 Source: IQVIA, as of December 31, 2017

A P P R O VA L W I T H N O N - I N F E R I O R I T Y C O U L D E N A B L E L A U N C H O F R E Z A F U N G I N

Ta r g e t s : o u t p a t i e n t s , e a r l y h o s p i t a l d i s c h a r g e a n d p r o p h y l a x i s s e g m e n t s

$4.2 Billion

$0.5 Polyenes

$1.1 Echinocandins

$2.6 Azoles

OUTPATIENT

INPATIENT

TREATMENTPROPHYLAXIS

AzolesAzoles/Bactrim

Rezafungin

Targets

Marketed

Echinocandins

Azoles/Bactrim

13 Source: IQVIA, as of December 31, 2017

R E Z A F U N G I N ' S G LO BA L O P P O RT U N I T Y S PA N S I D A N D H E M ATO LO GY

$ 4 . 2 B I L L I O N

GLOBAL ANTIFUNGAL MARKET

INFECTIOUS DISEASE

HEMATOLOGY

MOSTLY TREATMENTMOSTLY PROPHYLAXIS

Cancidas	Noxafil
(caspofungin)	(posaconazole)
~$700M	~$700M

14 Source: Global sales for Cancidas - IQVIA; Noxafil - 2018 Merck Annual Report. Antifungal market data from IQVIA, as of December 31, 2017.

U S R E Z A F U N G I N P EA K S A L ES O P P O RT U N I T Y: ~ $ 7 5 0 M

INFECTIOUS DISEASE

HEMATOLOGY

MOSTLY TREATMENT

MOSTLY PROPHYLAXIS

Rezafungin in Treatment	Rezafungin in Prevention
̴$375M	̴$375M

15		Revenue projections are for peak year 2032 based on estimates and assumptions, including estimated patient populations, market share and pricing assumptions. Actual results could differ materially. Prophylaxis revenue is an estimate of the peak
	sales potential, of which ~$223M is attributed to spontaneous product use that may occur outside of anticipated initial indication. Any such use will not be supported by Company promotion.

R E Z A F U N G I N OV E R A L L P H A S E 3 D E V E LO P M E N T P L A N

P H A S E 3 T R E A T M E N T T R I A L

P H A S E 3 P R O P H Y L A X I S T R I A L

POTENTIAL INDICATION	Treatment of candidemia & invasive
candidiasis

PHASE 3 SIZE

184 patients1 (20% NI margin)

OVERALL OBJECTIVE	Improve outcomes, allow early hospital discharge
and enable transition to outpatient use
	Expect topline data by end of 2021

Prophylaxis against Aspergillus, Candida &

Pneumocystis in allogeneic blood and

marrow transplant patients

462 patients (12.5% NI margin)

Transform post-blood & marrow

transplant standard of care

16	1.	Phase 3 Primary Evaluable Population size.

S T R I V E P H A S E 2 D A T A I N C A N D I D E M I A & I N V A S I V E C A N D I D I A S I S

P o s i t i v e d a t a s u p p o r t s R e S T O R E P h a s e 3 c l i n i c a l t r i a l

17

S T R I V E P H A S E 2 P RO G R A M : C A N D I D E M I A & I N VA S I V E C A N D I D I A S I S

Tr i a l n o t p o w e r e d f o r i n f e r e n t i a l s t a t i s t i c a l a n a l y s i s

				Overall Response
				(Mycological & clinical
N= 183				response)	Overall Response				All cause mortality				End of Follow Up Period
		Dose		Optional dose
Rezafungin
Week	1	2	3		4	5	6	7	8	9
N= 122	Day
			5		14					30

	Dose		Optional dose
Caspofungin	Week 1		2	3		4	5	6	7	8	9

N= 61

A N A LY S I S	• The Intent-to-treat (ITT) population: all randomized subjects
•	The Safety population: all subjects who received any amount of study drug
P O P U L A T I O N S :	•	The Microbiological Intent-to-treat population (mITT): all subjects in safety population who had
		documented Candida infection

18

R E Z A F U N G I N S H O W E D S U P E R I O R I T Y O N T I M E T O N E G A T I V E B L O O D C U L T U R E O V E R C A S P O F U N G I N

T I M E T O N E G AT I V E B L O O D C U LT U R E ( m I T T P O P U L AT I O N )

Probability of negative blood culture

100%	Rezafungin IV 400/200mg
80%	Caspofungin IV 70/50mg
60%	Daily doses
40%	Log-rank test (post hoc):
	RZF vs CSP
20%	p=0.02
Weekly
	Dose

0%	0	1	2	3	4	5	6	7	8
				Days since first dose

19 Data on file from STRIVE A and B combined

3 0 - DAY A L L C AU S E M O RTA L I T Y - P O S T H O C A N A LY S I S

FA V O R S R E Z A F U N G I N

-8.8%

-24.7% Rezafungin 400/200; n = 46

95% confidence interval

S U P E R I O R I T Y

F A V O R S C A S P O F U N G I N

ReSTORE Phase 3 trial endpoint requires upper limit of

+0.41%confidence interval be below

20% threshold for FDA

20%

Non-inferiority margin

N O N - I N F E R I O R I T Y

-20%

-10%

0

10%

		Using the same analysis method as planned for the Phase 3 study, a two-sided 95% confidence interval (CI) for the observed difference in the ACM rate (relevant Rezafungin group minus caspofungin
20		group) was calculated using the unadjusted method of Miettinen and Nurminen.
	Post-hoc analyses do not establish effectiveness and should not be assumed to establish the same outcome in Phase 3.

DAY 1 4 C L I N I C A L R ES P O N S E - P O S T H O C A N A LY S I S

F A V O R S R E Z A F U N G I N FA V O R S C A S P O F U N G I N

																ReSTORE Phase 3 trial endpoint
						9.9%										requires upper limit of
															confidence interval be below
26.6%	Rezafungin 400/200; n = 46					-6.9%					20% threshold for EMA
					95% confidence interval
													-20%
														Non-inferiority
															margin
						S U P E R I O R I T Y	N O N - I N F E R I O R	I T Y
20%	10%		0	-10%

Using the same analysis method as planned for the Phase 3 study, a two-sided 95% confidence interval (CI) for the observed difference in the ACM rate (relevant Rezafungin group minus caspofungin group) was calculated using the unadjusted method of Miettinen and Nurminen.

21 Post-hoc analyses do not establish effectiveness and should not be assumed to establish the same outcome in Phase 3.

S T R I V E P H A S E 2 : S H O R T E R A V E R A G E I C U S T A Y F O R P A T I E N T S O N R E Z A F U N G I N 1

% Neg. Blood Culture2

% Overall Cure

Average Days in ICU

74.4

54.2

1 DAY

73.9

55.7

5 DAYS

REZAFUNGIN

n/N

n/N

32/43

34/46

13 DAYS

32/59

34/61

CASPOFUNGIN

Rz Cf2

Rz

Cf

16 DAYS

Days 0

5

10

15

85.7

2 DAYS

3

65.5

2

n/N

36/42

Rz

Cf

38/58

% Neg. Blood Culture

ICU DAYS

SAVED

22 1. Data on File.

2. Proportion of patients with negative blood culture, mITT population (%; n/N).

R e S T O R E P H A S E 3 T R I A L D ES I G N M I R RO RS S T R I V E P H A S E 2 T R I A L

					Global	Global Response					All Cause Mortality		End of Follow Up Period
					Response	(1° ENDPOINT - EMA)			(1° ENDPOINT - FDA)
Rezafungin			Dose			Optional dose
Week	1		2	3		4	5	6	7	8	9
N= 92
400/200mg	Day
			5		14						30

Caspofungin	Dose		Optional dose
Week 1	2	3	4	5	6	7	8	9
N= 92
70/50mg

23	Global Response is defined as Clinical Response (as assessed by the Primary Investigator), Mycological Response and Radiological Response (for qualifying invasive candidiasis patients only).

T H E D I S A R M A C T: A F U N DA M E N TA L I M P ROV E M E N T I N R E I M B U RS E M E N T

The DISARM Act

Proposed, but not yet enacted, legislation to encourage the development of antimicrobial drugs

Currently proposed terms of the DISARM Act

• Removes QIDP-designated products - like rezafungin - from DRG1 reimbursement and, instead, allows for separate reimbursement
• Generic echinocandins are not QIDP-designated and would not be eligible for separate reimbursement under DISARM Act

DISARM Act status

• Bipartisan introduction in 2019 by Senators Isakson (R) and Casey (D) and Representatives Davis (D) and Marchant (R)
• Expected to be reintroduced in 117th Congress in early 2021

1. Co-sponsorsin the Senate and House affirm that this is a high priority

DISARM Act terms from H.R.4100 - 116th Congress (2019-2020).https://www.congress.gov/bill/116th-congress/house-bill/4100/text

24 1. Under the diagnosis-related group (DRG) payment system, health care providers receive a fixed payment based on the DRG assigned to the patient at discharge regardless of the cost of actually treating the patient.

R E Z A F U N G I N O V E R A L L P H A S E 3 D E V E L O P M E N T P L A N

P H A S E 3 T R E A T M E N T T R I A L

P H A S E 3 P R O P H Y L A X I S T R I A L

POTENTIAL INDICATION	Treatment of candidemia & invasive
candidiasis

PHASE 3 SIZE

184 patients1 (20% NI margin)

	Improve outcomes, allow early hospital discharge
OVERALL OBJECTIVE	and enable transition to outpatient use
	Expect topline data by end of 2021

Prophylaxis against Aspergillus, Candida &

Pneumocystis in allogeneic blood and

marrow transplant patients

462 patients (12.5% NI margin)

Transform post-blood & marrow

transplant standard of care

25

1.

Phase 3 Primary Evaluable Population size.

C U R R E N T A N T I F U N G A L P R O P H Y L A X I S S T A N D A R D O F C A R E I S I N A D E Q U A T E

H I G H D I S C O N T I N U AT I O N R AT E

BMT patients discontinue prophylaxis due to adverse

events and low tolerability

Posaconazole1	34%
Fluconazole 1	38%
Bactrim2	35%

H I G H M O R T A L I T Y

90-day mortality in patients with invasive fungal infection3

Blood and marrow transplant	63%
Hem Malignancy	52%

1. Ullmann AJ et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335-47.
2. Vasconcelles MJ et al. Aerosolzed Pentamidine and Pneumocystis Prophylaxis after Bone Marrow Transplantation is Inferior to Other Regimens and is Associated with Decreased Survival and Increased

26 Risk of Other Infections. A. Society for BMT. 2000.

3. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012.

R E Z A F U N G I N : P O T E N T I A L S I M P L I F I E D S I N G L E D R U G P A R A D I G M

A n t i f u n g a l p r o p h y l a x i s i n a l l o g e n e i c b l o o d a n d m a r r o w t r a n s p l a n t s e t t i n g

Current

Antifungal

Prophylaxis

Regimens

Fluconazole

Fluconazole

Posaconazole or voriconazole

Posaconazole or voriconazole

Bactrim, dapsone or atovaquone

Rezafungin 400/200 once weekly

-10	0	10	20	30	40	50	60	70	80	90
	Transplant							Day

SOC for Candida and Aspergillus

SOC for

Pneumocystis

Candida, Aspergillus and Pneumocystis

27

R e S P E C T P H A S E 3 P R O P H Y L A X I S T R I A L D E S I G N

REZAFUNGIN ARM (N=~300)	Dose					1° Endpoint: Fungal Free Survival at Day 90					Follow up
Week 1		2	3	4	5		12	13							17
Rezafungin
Azole placebo
Bactrim placebo
Day	1																90	120

COMPARATOR ARM (N=~150)
Week 1	2	3	4	5		12	13							17
Rezafungin Placebo
Azole1
Bactrim
Day	1											90	120

28	1. Fluconazole to start in all patients. Posaconazole optional in patients who develop GVHD per label.

P A T I E N T E X P E R I E N C E - E X P A N D E D A C C E S S

P a t i e n t A - r e s i s t a n t C . g l a b r a t a a n d t r e a t m e n t - i n d u c e d r e n a l f a i l u r e

B A C K G R O U N D

Outpatient adult male with multiple aortic surgeries and chronic Candida glabrata infection requiring life-long suppression

Initially treated with once daily

intravenous infusions of caspofungin

C L I N I C A L

O B S E R V A T I O N S

S I T U A T I O N	E X P A N D E D A C C E S S
The C. glabrata strain acquired an	On May 7, 2020 Patient A received
fks mutation that confers resistance to	the first 1x/weekly IV infusion of 400
the caspofungin treatment	mg of rezafungin
Patient A was switched to	Patient A continues to receive
amphotericin B and flucytosine,	1x/weekly IV infusions of 200 mg
but then developed renal failure	rezafungin as an outpatient
and was running out of
treatment options

• Chronic resistant C. glabrata infection remains suppressed to date
• Renal function recovered with discontinuation of amphotericin B; avoided dialysis
• To date, no adverse events related to this treatment

29	Patient A's response may not be typical of all patients. Individual results may vary. Information above is as of December 2020.

PAT I E N T E X P E R I E N C E - E X PA N D E D A C C ES S

P a t i e n t B - u n r e s o l v e d r e s i s t a n t i n f e c t i o n r e q u i r i n g e x t e n d e d i n p a t i e n t t r e a t m e n t

B A C K G R O U N D	S I T U AT I O N	E X PA N D E D A C C E S S
Inpatient adult female with recent	Patient B was not considered a	Patient B administered 400 mg of
liver transplant complicated by	good candidate for additional	rezafungin the first week followed by
intra-abdominal abscesses with	surgery	1x/weekly doses of 200 mg rezafungin
chronic Candida krusei	Physician believed infection was	Patient B improved and was discharged,
Infection did not clear with
unresponsive to treatment due to	while continuing to receive 1x/weekly
repeated surgical washouts and	inadequate tissue penetration of	200 mg rezafungin on an
prior antifungal therapy with	prior echinocandin therapy	outpatient basis
micafungin		12 total treatments

	• Patient B responded to 1x/weekly rezafungin IV treatments, was discharged and able to continue 1x/weekly treatment as
C L I N I C A L	an outpatient
O B S E R V A T I O N S	• Imaging at week 12 confirmed that the critical deep tissue infection was resolved and Patient B was able to cease treatment
	• To date, no adverse events related to this treatment

30 Patient B's response may not be typical of all patients. Individual results may vary.

O U R P A R T N E R F O R R E Z A F U N G I N E X - U S / J A P A N

1 2 0

M A R K E T S

Active in more than 30

in Europe

O v e r € 2

B I L L I O N

European sales

exceeding €1 billion

Over €2B ex-US

Y E6A0R S

Over 60 years of

asset-led innovation

5 0 %

Over 50% revenue derived from new products launched in the last five years in Europe

Product: Rezafungin | Rights: ex-US/Japan

$ 5 6 8 M

P h a s e 2 d a t a

• $30M upfront
• $9M equity investment
• Up to $42M in development support
• Up to $487M clin/reg/comm milestones
• Double-digitroyalties in the teens

31

C I D A R A ' S P I P E L I N E T A R G E T S M U L T I P L E U N M E T M E D I C A L N E E D S

REZAFUNGINCLOUDBREAK

ANTIFUNGALANTIVIRAL

32

C L O U D B R E A K AV C P L AT FO R M : A P OT E N T I A L N E W C L A S S O F A N T I V I R A L

ANTIVIRAL CONJUGATE (AVC)

A POTENTIAL NEW CLASS OF LONG-ACTING DRUGS

• Not a vaccine, monoclonal antibody or traditional therapeutic
• AVCs designed to be stable conjugates of a potent antiviral with an Fc antibody fragment
• Designed for rapid onset, potent activity coupled with ̴4 - 6 months of protection

33

C L O U D B R E A K A V C s : P O T E N T I A L T O T A R G E T M U L T I P L E V I R U S E S

T W O P R O D U C T O P P O R T U N I T I E S F O R I N F L U E N Z A

C D 3 7 7	C D 3 8 8
(Development Candidate)	(Development Candidate)

•	Single dose / ̴4 months	•	Single dose / 6̴ months
•	Full immune engagement	•	Attenuated immune engagement
PLATFORM EXPANSION	RSV		HIV	SARS-CoV-2
PROGRAMS UNDERWAY

34

C L O U D B R E A K I N F L U E N Z A A V C s : A F U N D A M E N T A L L Y N E W A P P R O A C H

Potential Design Benefits

Potent, universal activity against

influenza A and B

̴4 - 6 months of protection Engages immune system

Neuraminidase	Fc domain of
inhibitor	human IgG1

35

A V C s M E C H A N I S M O F A C T I O N A G A I N S T I N F L U E N Z A

FLU VIRUS REPLICATION

CD377 / CD388 ACTIVITY AGAINST FLU

				NEURAMINIDASE
				RELEASE OF			VIRION	NO VIRION
			VIRION			RELEASED	HALTED
NEURAMINIDASE			NEW VIRIONS	CONTINUED
		AVC INHIBITS			VIRAL
CLEAVES RECEPTOR					VIRAL
					REPLICATION
					REPLICATION	NEURAMINIDASE
					ACTIVITY
BUDDING	RECEPTOR			RECEPTOR
		CONTAINING SIALIC
VIRUS	CONTAINING SIALIC
		ACID
			ACID
H O S T	C E L L			H O S T	C E L L

36

F L U V A C C I N E S H A V E W E L L - K N O W N L I M I T A T I O N S

Historically flu vaccine effectiveness has been limited

Flu vaccines don't cover all strains

Flu vaccines don't cover most people

• Vaccines cover 3 to 4 of the dozens of flu strains
• Strains selected 6 months before the flu season
• Flu viruses are constantly changing
• Certain strains (H3N2) grow poorly in eggs

		2018-2019 flu season
		Age	Vaccine
		Effectiveness
Vaccine	6 mos-8 y	48%
Effectiveness (VE)
9-17 y	7%
in 2018-2019
29%	18-49 y	25%
		50-64 y	14%
		≥65 y	12%

37 Centers for Disease Control and Prevention: Selecting Viruses for the Seasonal Influenza Vaccine and Seasonal influenza vaccine effectiveness.

~ 1 0 0 M P E O P L E I N U S A T H I G H R I S K F O R F L U C O M P L I C A T I O N S 1 , 2

Many higher risk patients have lower Vaccine Effectiveness

Immuno-	Pregnant	Elderly	Children	Respiratory co-
compromised3	women	over 65	under 5	morbidities4
		HIGH RISK

1. High risk groups:https://www.cdc.gov/flu/highrisk/index.htm
2. Census Bureau 2017, CDC.gov and cancer.gov

38 3. The Prevalence of Immunocompromised Adults: United States, 2013. Harpaz. JAMA December 20, 2016 Volume 316, Number 23

4. Includes asthma and COPD

V I S I O N F O R A V C s : S I N G L E - D O S E , U N I V E R S A L , S E A S O N A L P R O T E C T I O N

AVC VISION

AVCs designed to cover

AVCs aim to protect

ALL STRAINS ALL PEOPLE

39

P R E - C L I N I C A L V A L I D A T I O N O F A V C F L U P R O G R A M

BROAD SPECTRUM COVERAGE	PROTECTION FOR HIGH-RISK
POPULATIONS

POTENCY VS.	PROLONGED SINGLE-DOSE
TAMIFLU-RESISTANT VIRUSES	PROTECTION

SUPERIOR RESISTANCE PROFILE

BROAD SAFETY MARGIN

40

C D 3 7 7 : E F F E C T I V E I N V I V O A G A I N S T A L L F L U A & B S T R A I N S T E S T E D

L E T H A L I N F L U E N Z A I N F E C T I O N M O D E L S

	CD377 - 0.3 mg/kg
A/California/07/2009	Vehicle	A/Hong Kong/1/68 H3N2
H1N1 Pandemic

CD377 - 0.03 mg/kg

B/Florida/4/2006	B/Malaysia (Victoria)
(Yamagata)
Vehicle

CD377 - 0.3 mg/kg Vehicle

CD377 - 0.1 mg/kg

Vehicle

41 5 BALB/c mice per cohort. CD377 dosed once 2 hours post infection (SC). Döhrmann and Levin et al, IDWeek 2020

C D 3 7 7 : P O T E N T A G A I N S T T A M I F L U - R E S I S T A N T V I R U S E S

L E T H A L I N F L U E N Z A I N F E C T I O N M O D E L

Dose

Doses

Survival	Tamiflu 20 mg/kg
%	BID x 5

CD377 - 0.3 mg/kg dosed once

Vehicle

Days Post Infection

42 5 mice per cohort. CD377 dosed 2 hours post infection (SC), Tamiflu dose 2 hours post infection BID x 5 days (PO). Levin et al, IDWeek 2020

C D 3 7 7 : L O W E R R E S I S T A N C E P O T E N T I A L

Viral titer, (PFU/mL)

S E R I A L P A S S A G E S T U D Y

107

				Vehicle		Tamiflu (100 nM)
						Baloxavir (4 nM)
108
105
						CD377 (4 nM)
104
103	2	4	6	8	10

Passage Number

43 Almaguer et al, ECCMID 2020

C D 3 7 7 : P O T E N T I A L F O R L O N G - T E R M , S I N G L E D O S E P R O T E C T I O N

Single 1 mg/kg SC dose was fully protective vs:

• H1N1 (right)
• A/Hong Kong/1/68 H3N2
• Influenza B (Malaysia)
• Influenza B (Florida)

L O N G T E R M P R E V E N T I O N M O D E L

CD377: 1 mg/kg

% Survival

Vehicle

DoseInfect

Day Post Infection

44 5 mice per cohort. CD377 dosed 28 days prior to infection (SC). Levin et al, IDWeek 2020

C D 3 7 7 : E F F E C T I V E I N I M M U N E D E F I C I E N T H O S T S

LETHAL INFLUENZA INFECTION MODELS

BALB/c immune competent	SCID immune deficient
CD377 - 0.1mg/kg	CD377 - 0.1mg/kg

Vehicle

Vehicle

45 5 BALB/c or SCID mice per cohort. CD377 dosed once 2 hours post A/PR/8/1934 H1N1 infection (SC). Levin et al, IDWeek 2020

C D 3 7 7 : B R O A D S A F E T Y M A R G I N I N P R I M A T E S

R e s u l t s o f 1 4 - d a y t o x i c i t y t e s t i n g

THERAPEUTIC MARGIN

500000

Area under the curve (AUC) for maximum dose tested (hr*mg/mL)

25000095x

Predicted AUC required for efficacy in humans (hr*mg/mL)

0

Primate

NO ADVERSE FINDINGS FOR:

Clinical observations

Hematology

Clinical Chemistry

Coagulation

Urinalysis

Immunophenotyping

Cytokines

Histopathology

46 Cidara data on file

F I N A N C I A L O V E R V I E W

Important Information	September 30, 20201

Cash and restricted cash	$53.7M
PacWest Term Loan - Remaining Principal	$8.1M
Expected Mundipharma Milestone2	$11.1M
Common stock issued	43,936,026
Common equivalent shares issued3	54,378,806

Summary Consolidated

Cash Flow Information

Operating Cash Burn5

Mundipharma Cost Share Payments

Net Operating Cash Burn

ATM Equity Proceeds

Term Loan Principal Payments

Net Cash Use

Rolling two-quarter period ended September 30, 20204

$(36.8)M

$8.6M

$(28.2)M

$9.5M

$(1.9)M

$(20.6)M

1. Information listed here is as of September 30, 2020 (as disclosed in our 10-Q filing) with the exception of the Expected Mundipharma Milestone (see footnote 2).
2. As of November 27, 2020, Cidara met the necessary conditions under the Collaboration and License Agreement with Mundipharma dated September 3, 2019 to require Mundipharma to pay the previously disclosed $11.1 million milestone payment on or before January 10, 2021.
3. Includes (i) 43,936,026 shares of common stock and (ii) 10,442,780 shares of common stock issuable upon the conversion of Series X Convertible Preferred stock, both as of September 30, 2020. Each share of

Series X Convertible Preferred is convertible into 10 shares of common stock.

47 4. Amounts reflect a rolling two quarter period ending on the date noted. Amounts shown are historical and may not be indicative of future results.

5. Represents net cash used in operations of $28.2M adjusted to remove $8.6M received pursuant to the Mundipharma cost share.

C I DA R A I S M U C H M O R E T H A N A T Y P I C A L I D CO M PA N Y

S T R AT E G I C F O C U S

R E Z A F U N G I N

T R E AT M E N T

R E Z A F U N G I N P R O P H Y L A X I S

Transformative approaches to infectious disease

Potential to enable fast clearance of infection, early discharge vs SOC

Potential to transform the care of BMT patients

C L O U D B R E A K A V C

Radically different approach to prevent and treat viral disease

O U R T E A M

Experienced creators of shareholder value

48

CORPORATE PRESENTATION

49	L E A D I N G T H E S C I E N C E O F P R O T E C T I O N